DD144667A5 - Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern - Google Patents

Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern Download PDF

Info

Publication number
DD144667A5
DD144667A5 DD79213967A DD21396779A DD144667A5 DD 144667 A5 DD144667 A5 DD 144667A5 DD 79213967 A DD79213967 A DD 79213967A DD 21396779 A DD21396779 A DD 21396779A DD 144667 A5 DD144667 A5 DD 144667A5
Authority
DD
German Democratic Republic
Prior art keywords
compound
general formula
och
dihydropyridine
ester
Prior art date
Application number
DD79213967A
Other languages
German (de)
English (en)
Inventor
Peder B Berntsson
Stig A I Carlsson
Jan Oe Gaarder
Bengt R Ljung
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20335348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD144667(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of DD144667A5 publication Critical patent/DD144667A5/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DD79213967A 1978-06-30 1979-06-28 Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern DD144667A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7807404A SE429652B (sv) 1978-06-30 1978-06-30 2.6-dimetyl-4-(2.3-diklorfenyl)-1.4-dihydropyridin-3.5-dikarboxylsyra-3-metylester-5-etylester

Publications (1)

Publication Number Publication Date
DD144667A5 true DD144667A5 (de) 1980-10-29

Family

ID=20335348

Family Applications (1)

Application Number Title Priority Date Filing Date
DD79213967A DD144667A5 (de) 1978-06-30 1979-06-28 Verfahren zur herstellung von 2,6-dimethyl-4-phenyl-1,4-dihydropyridin-3,5-dicarbonsaeurediestern

Country Status (24)

Country Link
US (1) US4264611A (enExample)
EP (1) EP0007293B1 (enExample)
JP (1) JPS559083A (enExample)
AT (1) ATE1237T1 (enExample)
AU (1) AU529116B2 (enExample)
BG (1) BG61420B2 (enExample)
CA (1) CA1117530A (enExample)
CS (1) CS241021B2 (enExample)
CY (1) CY1299A (enExample)
DD (1) DD144667A5 (enExample)
DE (1) DE2963150D1 (enExample)
DK (1) DK148978C (enExample)
FI (1) FI70573C (enExample)
HK (1) HK60585A (enExample)
HU (1) HU178568B (enExample)
IE (1) IE48650B1 (enExample)
LU (2) LU88666I2 (enExample)
NL (2) NL930054I2 (enExample)
NO (3) NO151965C (enExample)
NZ (1) NZ190809A (enExample)
SE (1) SE429652B (enExample)
SG (1) SG26085G (enExample)
SU (2) SU856380A3 (enExample)
ZA (1) ZA792804B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2935451A1 (de) * 1979-09-01 1981-03-19 Bayer Ag, 5090 Leverkusen Optisch aktive 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arneimittel
SE7910521L (sv) * 1979-12-20 1981-06-21 Haessle Ab Nya 2-metyl-6-substituerade-4-(2,3-disubstituerad fenyl)-1,4-dihydropyridin-3,5-diestrar med hypotesiva egenskaper, samt forfarande for deras framstellning, och farmaceutiska beredningar innehallande desamma
IL68604A0 (en) * 1982-05-21 1983-09-30 Haessle Ab Processes for preparing therapeutically active dihydropyridines and intermediates for the processes
US4656181A (en) * 1982-11-24 1987-04-07 Cermol S.A. Esters of 1,4-dihydropyridines, processes for the preparation of the new esters, and medicaments containing the same
DE3307422A1 (de) * 1983-03-03 1984-09-06 Bayer Ag, 5090 Leverkusen Fluessigzubereitungen von dihydropyridinen, ein verfahren zu ihrer herstellung, sowie ihre verwendung bei der bekaempfung von erkrankungen
AU561213B2 (en) * 1983-06-02 1987-04-30 Teijin Limited 1, 4-dihydropyridine derivative
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
FI852359A7 (fi) * 1984-06-27 1985-12-28 F Hoffmann La Roche & Co Dihydropyridiinijohdannaisia.
US4757071A (en) * 1984-12-14 1988-07-12 Nisshin Flour Milling Co., Ltd. 1,4-dihydropyridine derivatives, and pharmaceutical compositions containing same, useful for treating cardiovascular diseases
DE3447169A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Optisch aktive nitrodihydropyridine, verfahren zur herstellung und ihre verwendung in arzneimitteln
DE3447170A1 (de) * 1984-12-22 1986-07-03 Bayer Ag, 5090 Leverkusen Mischung unterschiedlicher dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
NZ220022A (en) * 1986-04-22 1990-04-26 Byk Gulden Lomberg Chem Fab 1,4-dihydropyridine derivatives and pharmaceutical compositions
US4920225A (en) * 1986-12-22 1990-04-24 Laboratoires Syntex S.A. Resolution of 1,4-dihydropyridine derivatives
JPS63255071A (ja) * 1987-04-14 1988-10-21 株式会社　岡田吾作郎商店 磁石内蔵健康棒
AT391269B (de) * 1988-12-30 1990-09-10 Burghart Kurt Pharmazeutische zubereitung
US5310917A (en) * 1991-09-13 1994-05-10 Merck & Co., Inc. Process for the preparation of 4-substituted-1,4-dihydropydrines
US5834496A (en) * 1991-12-02 1998-11-10 Sepracor, Inc. Methods for treating hypertension using optically pure S(-) felodipine
WO1993010781A1 (en) * 1991-12-02 1993-06-10 Sepracor, Inc. Methods and compositions for treating hypertension, angina, and other disorders using optically pure s(-) felodipine
EP0657432B1 (de) * 1993-12-10 2003-03-12 Bayer Ag Phenyl-substituierte 1,4-Dihydropyridine mit cerebraler Aktivität
DE4430639A1 (de) * 1994-08-29 1996-03-07 Bayer Ag Verwendung von 5-substituierten Pyridin- und Hexahydrochinolin-3-carbonsäurederivaten
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5977369A (en) * 1995-12-28 1999-11-02 Napp Technologies, Inc. Process to prepare dihydropyridine and derivatives thereof
SE9600086D0 (sv) * 1996-01-10 1996-01-10 Astra Ab New manufacturing process
IT1283793B1 (it) * 1996-08-23 1998-04-30 Lusochimica Spa Processo per la preparazione di diidropiridine
WO2000005209A1 (fr) * 1998-07-23 2000-02-03 Lin, Tong-Ho GUAIACOXYPROPANOLAMINES A ACTIVITE α/β-ADRENOLYTIQUE
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6569456B2 (en) 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic
BR0109991A (pt) * 2000-04-11 2003-05-27 Sankyo Co Composição farmacêutica
US6653481B2 (en) * 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
EA200500234A1 (ru) 2002-08-19 2005-08-25 Пфайзер Продактс Инк. Комбинированная терапия гиперпролиферативных болезней
SG141430A1 (en) * 2003-05-30 2008-04-28 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as hmg-co inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
AU2007274724B2 (en) * 2006-07-14 2012-07-26 Ranbaxy Laboratories Limited Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US8748648B2 (en) 2007-09-06 2014-06-10 Nektar Therapeutics Oligomer-calcium channel blocker conjugates
CA2705097A1 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
WO2012123966A1 (en) 2011-03-04 2012-09-20 Arch Pharmalabs Limited Process for the preparation of 4 -substituted -1, 4-dihydropyridines
CN102827068A (zh) * 2011-06-17 2012-12-19 张锐豪 一种4-(2, 3-二氯苯基)-2, 6-二甲基-1, 4-二氢-5-甲氧基羰基-3-吡啶羧酸的制备方法
KR101708538B1 (ko) 2011-08-26 2017-02-20 욱크하르트 리미티드 심혈관 질환의 치료 방법
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
CN104177286A (zh) * 2014-08-11 2014-12-03 广东东阳光药业有限公司 一种地平类药物的制备方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR101824982B1 (ko) 2015-10-07 2018-02-02 엘지전자 주식회사 차량 및 그 제어방법
CN107952483B (zh) * 2017-12-18 2020-07-28 万华化学集团股份有限公司 一种催化剂，使用该催化剂的反应器，以及一种制备β-苯乙醇的方法
CN108840819B (zh) * 2018-04-02 2021-07-30 常州瑞明药业有限公司 一种非洛地平的制备方法
CN112955965B (zh) 2018-06-14 2024-04-09 阿斯利康(英国)有限公司 使用二氢吡啶类钙通道阻断剂医药组合物降低血压的方法
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
DE1670824C3 (de) * 1967-03-20 1978-08-03 Bayer Ag, 5090 Leverkusen 1,4-Dihydropyridin-33-dicarbonsäurealkylester
DE2117572C3 (de) * 1971-04-10 1980-03-20 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin ^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2117573C3 (de) * 1971-04-10 1978-07-27 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von unsymmetrischen l,4-Dihydropyridin-3,5dicarbonsäureestern, sowie ihre Verwendung als Arzneimittel
DE2117571C3 (de) * 1971-04-10 1979-10-11 Bayer Ag, 5090 Leverkusen Unsymmetrische 1,4-Dihydropyridin-33-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2210672C3 (de) * 1972-03-06 1980-03-20 Bayer Ag, 5090 Leverkusen N-substituierte unsymmetrische 1 ^-Dihydropyridin-S^-dicarbonsäureester, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
GB1552911A (en) * 1975-07-02 1979-09-19 Fujisawa Pharmaceutical Co 1,4 dihydropyridine derivatives and the preparation thereof

Also Published As

Publication number Publication date
CS241021B2 (en) 1986-03-13
NL940012I1 (nl) 1994-08-01
SE7807404L (sv) 1979-12-31
SG26085G (en) 1986-01-24
NO1994026I1 (no) 1994-12-21
LU88666I2 (fr) 1996-02-01
FI792058A7 (fi) 1979-12-31
US4264611A (en) 1981-04-28
EP0007293B1 (en) 1982-06-23
DK148978B (da) 1985-12-09
HK60585A (en) 1985-08-23
DK148978C (da) 1986-08-18
SU856380A3 (ru) 1981-08-15
JPS6121550B2 (enExample) 1986-05-27
FI70573B (fi) 1986-06-06
ZA792804B (en) 1980-06-25
SU915799A3 (en) 1982-03-23
IE791217L (en) 1979-12-30
SE429652B (sv) 1983-09-19
AU4831679A (en) 1980-02-07
DE2963150D1 (en) 1982-08-12
EP0007293A1 (en) 1980-01-23
NO151965B (no) 1985-04-01
NO792112L (no) 1980-01-03
CY1299A (en) 1985-10-18
CA1117530A (en) 1982-02-02
HU178568B (en) 1982-05-28
NZ190809A (en) 1982-03-09
NL930054I1 (nl) 1993-09-01
DK275079A (da) 1979-12-31
BG61420B2 (bg) 1997-07-31
AU529116B2 (en) 1983-05-26
NO1996006I1 (no) 1996-06-24
FI70573C (fi) 1986-09-24
US4264611B1 (enExample) 1984-07-17
JPS559083A (en) 1980-01-22
LU88306I2 (fr) 1994-05-04
ATE1237T1 (de) 1982-07-15
NO151965C (no) 1985-07-10
IE48650B1 (en) 1985-04-03
NL930054I2 (nl) 1994-02-16

Similar Documents

Publication Publication Date Title
US4264611A (en) 2,6-Dimethyl-4-2,3-disubstituted phenyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid-3,5-asymmetric diesters having hypotensive properties, as well as method for treating hypertensive conditions and pharmaceutical preparations containing same
DE69831869T2 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
DE3877492T2 (de) Pharmazeutisches praeparat mit verzoegerter abgabe eines dihydropyridins und eines beta-adrenorezeptor-antagonisten und herstellungsverfahren dessen.
EP0702953B1 (de) Darreichungsformen enthaltend feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE60217932T2 (de) Kristalline Zusammensetzung enthaltend Escitalopram
CH648484A5 (de) Pharmazeutische zubereitung eines festen medikamentmaterials.
DE1106454B (de) UEberzugsmittel fuer Arzneistoffe
AT5874U1 (de) Pharmazeutische zubereitungen enthaltend amlodipinmaleat
DD155519A5 (de) Verfahren zur herstellung von 2-methyl-4-(2,3-dichlorphenyl)-1,4-dihydropyridin-3,5-dicarbonsaeure-3,5-diestern
DE69723024T2 (de) Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung zur oralen Verabreichung enthaltend Nifedipin als Wirkstoff
DE3212736A1 (de) Verwendung von dihydropyridinen in arzneimitteln mit salidiuretischer wirkung
DE4423177A1 (de) Antihyperglykämisch wirksame Arzneimittel
EP0163984A2 (de) Dihydropyridinkombinationspräparate und Verfahren zu ihrer Herstellung
DE3586817T2 (de) 1,4-dihydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3787319T2 (de) 1,4-Dihydropyridin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
EP0081748A2 (de) Verfahren zur Herstellung von (-)-2-(1-(2,6-Dichlorphenoxy)-ethyl)-1,3-diazacyclopent-2-en
DE3830749A1 (de) Arzneimittel in form von kuegelchen mit hohem arzneistoffgehalt und verfahren zu ihrer herstellung
DD209816A5 (de) Verfahren zur herstellung von dihydropyridinen
DE3736866A1 (de) Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DD208614A5 (de) Verfahren zur herstellung von dihydropyridinen
DE2707763A1 (de) Verwendung von vincamin zur behandlung von kreislauferkrankungen des gehirns und dazu geeignetes arzneimittel
CH636337A5 (en) Process for preparing novel amines having beta receptor-inhibiting activity
AT363067B (de) Verfahren zur herstellung von neuen 3-phenoxy-2-hydroxy-1-phenoxy- oder -1-phenylthioalkylamino-propanen und von deren saeureadditionssalzen
AT353250B (de) Verfahren zur herstellung von neuen 3-phenoxy-2 -hydroxy-1-phenoxy- oder -1- phenylthioalkyl- amino-propanen und von deren saeureadditions- salzen
DE602005004033T2 (de) Venlafaxin enthaltende pharmazeutische teilchenförmige zusammensetzung mit verzögerter freisetzung